Conclusions
intellectual disabilities
SECONDARY
In this pragmatic trial, we did not find significant differences in the primary and secondary effectiveness between the supplement and placebo arms among people with intellectual disabilities. Since the COVID‐19 pandemic coincided with our trial, we recommend a replication of our study.